TRAEs
| TRAEs (N = 243) . | Any grade . | Grade 3 or 4 . |
|---|---|---|
| Patients with TRAEs, n (%) | 198 (81.5) | 67 (27.6) |
| TRAEs occurring in ≥10% of patients, n (%) | ||
| Fatigue | 61 (25.1) | 2 (0.8) |
| Diarrhea | 39 (16.0) | 2 (0.8) |
| Infusion-related reaction | 34 (14.0) | 1 (0.4) |
| Rash | 29 (11.9) | 2 (0.8) |
| Nausea | 27 (11.1) | 0 |
| Pruritus | 25 (10.3) | 0 |
| Immune-mediated AEs within 100 d of last dose | ||
| Hypothyroidism/thyroiditis | 35 (14.4) | 0 |
| Rash | 29 (11.9) | 4 (1.6) |
| Hepatitis | 15 (6.2) | 12 (4.9) |
| Pneumonitis | 15 (6.2) | 2 (0.8) |
| Hypersensitivity/infusion reactions | 13 (5.3) | 2 (0.8) |
| Diarrhea/colitis | 6 (2.5) | 5 (2.1) |
| Hyperthyroidism | 6 (2.5) | 0 |
| Nephritis and renal dysfunction | 3 (1.2) | 1 (0.4) |
| Diabetes mellitus | 2 (0.8) | 1 (0.4) |
| Adrenal insufficiency | 1 (0.4) | 0 |
| TRAEs (N = 243) . | Any grade . | Grade 3 or 4 . |
|---|---|---|
| Patients with TRAEs, n (%) | 198 (81.5) | 67 (27.6) |
| TRAEs occurring in ≥10% of patients, n (%) | ||
| Fatigue | 61 (25.1) | 2 (0.8) |
| Diarrhea | 39 (16.0) | 2 (0.8) |
| Infusion-related reaction | 34 (14.0) | 1 (0.4) |
| Rash | 29 (11.9) | 2 (0.8) |
| Nausea | 27 (11.1) | 0 |
| Pruritus | 25 (10.3) | 0 |
| Immune-mediated AEs within 100 d of last dose | ||
| Hypothyroidism/thyroiditis | 35 (14.4) | 0 |
| Rash | 29 (11.9) | 4 (1.6) |
| Hepatitis | 15 (6.2) | 12 (4.9) |
| Pneumonitis | 15 (6.2) | 2 (0.8) |
| Hypersensitivity/infusion reactions | 13 (5.3) | 2 (0.8) |
| Diarrhea/colitis | 6 (2.5) | 5 (2.1) |
| Hyperthyroidism | 6 (2.5) | 0 |
| Nephritis and renal dysfunction | 3 (1.2) | 1 (0.4) |
| Diabetes mellitus | 2 (0.8) | 1 (0.4) |
| Adrenal insufficiency | 1 (0.4) | 0 |